CHRISTOPHER S. HENNEY, PH.D., D.SC.

Corporate Board Profile

Tech Score: 0/100

Cyclacel Pharmaceuticals, Inc.

Filing Date	Source Excerpt
2009-04-30	Dr. Henney had served as one of Xcyte’s directors since March 2005, and continued on as Vice Chairman of the Company. Previously, Dr. Henney co-founded three major publicly held U.S. biotechnology companies, Immunex, ICOS and Dendreon, and held a seat on the board of directors and executive positions at each company. From 1995 to January 2003, Dr. Henney was Chairman and Chief Executive Officer of Dendreon Corporation. Dr. Henney currently serves as Chairman of Oncothyreon, Inc. and is a director of AVI BioPharma Inc. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham and a D.Sc. from the same university for contributions to the field of immunology.

Filing Date

Source Excerpt

2009-04-30

Dr. Henney had served as one of Xcyte’s directors since March 2005, and continued on as Vice Chairman of the Company. Previously, Dr. Henney co-founded three major publicly held U.S. biotechnology companies, Immunex, ICOS and Dendreon, and held a seat on the board of directors and executive positions at each company. From 1995 to January 2003, Dr. Henney was Chairman and Chief Executive Officer of Dendreon Corporation. Dr. Henney currently serves as Chairman of Oncothyreon, Inc. and is a director of AVI BioPharma Inc. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham and a D.Sc. from the same university for contributions to the field of immunology.

Sarepta Therapeutics, Inc.

Filing Date	Source Excerpt
2010-05-04	Christopher S. Henney, Ph.D., D.Sc.(2)(4) 24,000 Fees Earned or Paid in Cash, 33,498 Option Awards, Total 57,498

Data sourced from SEC filings. Last updated: 2026-02-03